Depomed submits Proquin XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Depomed files its once-daily, extended-release ciprofloxacin formulation Proquin XR for treatment of uncomplicated urinary tract infections, the firm announces July 20. The NDA is based on a single Phase III trial in 1,037 patients comparing a three-day course of Proquin XR to three days of twice-daily immediate release ciprofloxacin (Bayer's Cipro). The study showed an eradication rate of 93.4% for Proquin XR compared to 89.6% for Cipro. Depomed will highlight fewer gastrointestinal side effects; in the clinical trial Proquin patients had "five-fold fewer complaints of nausea and seven-fold fewer cases of diarrhea." Depomed's Gastric Retention technology provides for "preferential absorption in the upper intestine." The company is "in discussions with potential marketing partners" and "evaluating the opportunity to co-promote the product in certain markets"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.